Curia (RNA/Advanced) vs Kaneka Eurogentec: CDMO Comparison

How does Curia (RNA/Advanced) compare to Kaneka Eurogentec?

As of Aug 2026, Curia (RNA/Advanced): 2 FDA inspections (including 1 NAI, 1 VAI and 0 OAI), 18 EMA/MHRA GMP certificates. Signal Score 79.5. Kaneka Eurogentec: 1 FDA inspection (including 0 NAI, 1 VAI and 0 OAI), 4 EMA/MHRA GMP certificates. Signal Score 81.6. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.

Side-by-side comparison of Curia (RNA/Advanced) and Kaneka Eurogentec on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Albany, NY · Albuquerque, NM
Signal Score
80/100
Quality (FDA + GMP)
100/100
FDA inspections
2
— NAI / VAI / OAI
1 / 1 / 0
FDA warning letters
0
EMA GMP certificates (active)
18
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
0
Capacity
—
Modalities
mRNA, Oligonucleotide, Biologics
Seraing, BE
Signal Score
82/100
Quality (FDA + GMP)
100/100
FDA inspections
1
— NAI / VAI / OAI
0 / 1 / 0
FDA warning letters
0
EMA GMP certificates (active)
4
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
0
Capacity
—
Modalities
mRNA, Plasmid, Oligonucleotide

Key differences

  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • Curia (RNA/Advanced) has materially broader EMA GMP coverage (18 active certificates vs 4) — stronger EU footprint.

Across the cross-modality scorecard, Kaneka Eurogentec carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.

Frequently asked: Curia (RNA/Advanced) vs Kaneka Eurogentec

How does Curia (RNA/Advanced) compare to Kaneka Eurogentec?

On CDMO Signal's composite Signal Score, Curia (RNA/Advanced) is 80/100 and Kaneka Eurogentec is 82/100; Curia (RNA/Advanced) has 2 FDA inspections on record vs 1 for Kaneka Eurogentec; European coverage is 18 active EMA+MHRA certificates for Curia (RNA/Advanced) vs 4 for Kaneka Eurogentec. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

Which has the stronger FDA inspection record, Curia (RNA/Advanced) or Kaneka Eurogentec?

Both Curia (RNA/Advanced) and Kaneka Eurogentec maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Curia (RNA/Advanced) has 2 FDA inspections on record; Kaneka Eurogentec has 1.

How do Curia (RNA/Advanced) and Kaneka Eurogentec compare on European GMP coverage?

Curia (RNA/Advanced) holds 18 active EMA GMP certificates and 0 MHRA / UK certificates. Kaneka Eurogentec holds 4 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

What does the Signal Score gap mean in practice?

Curia (RNA/Advanced) carries a Signal Score of 80/100 and Kaneka Eurogentec carries 82/100 — essentially tied for Kaneka Eurogentec. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating Curia (RNA/Advanced) and Kaneka Eurogentec for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.